---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-24-000011"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:54:49.570689+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics Q1 net loss $4.6M; cash $10.5M funds operations into Q1 2025

## Summary
- Net loss of $4.6M in Q1 2024 vs $1.3M in Q1 2023; R&D expenses rose to $2.8M from $0.8M, G&A to $1.9M from $0.5M.
- Cash, cash equivalents and marketable debt securities totaled $10.5M as of Mar 31, 2024; expected to fund operations through Q1 2025.
- Intends to initiate Phase 3 INVINCIBLE-3 Study in mid-2024: INT230-6 monotherapy vs SOC in soft tissue sarcoma, 333 patients, overall survival endpoint.
- Intends to initiate Phase 2/3 INVINCIBLE-4 Study in mid-2024: INT230-6 + SOC in neoadjuvant triple negative breast cancer, endpoint pCR.
- Over 30 sites screened for INVINCIBLE-3; contracts in process; Phase 3 clinical supplies released and shipped.

## SEC filing metadata
- accession: 0001567264-24-000011
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/0001567264-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/intensity-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-24-000011
- JSON: https://secwatch.observer/filing/0001567264-24-000011.json
- Plain text: https://secwatch.observer/filing/0001567264-24-000011.txt

## Key facts
- Earnings Releases
  INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: net income Net loss was $4.6 million.
  - Period: the three months ended March 31, 2024
  - Net income: Net loss was $4.6 million
  - Result: reported results
  source text: On May 9, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000011/0001567264-24-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.